Angiotensin II (AII) is the active octapeptide product of the renin enzymatic cascade, which is responsible for sustaining blood pressure. In an attempt to establish the AII-receptor-bound conformation of this octapeptide, we designed conformationally constrained analogues by scanning the entire AII sequence with an i-(i + 2) and i-(i + 3) lactam bridge consisting of an Asp-(Xaa) n -Lys scaffold. Most analogues presented low agonistic activity when compared to AII in the different bioassays tested. increase in biological activity when compared with peptide (1) and were equipotent to AII. In contrast, six analogues presented antagonistic activity. These results suggest that the position of the lactam bridge is more important than the bridge length or chirality for recognition of and binding to the angiotensin II AT1-receptor.
Introduction
Angiotensin II (AII) is a natural peptide produced in the blood as a result of two different enzymatic hydrolyses that takes place in the renal hypertension system [1] . Kidney juxtaglomerular cells [2] , in certain circumstances, liberate an enzyme called renin that acts on the full protein substrate angiotensinogen to liberate the angiotensin I peptide [3] . This decapeptide is hydrolyzed by the angiotensinconverting enzyme to generate the peptide AII [4, 5] . The reninangiotensin system plays an important role in the regulation of blood pressure. AII, the hormone responsible for this physiological function, interacts with several tissues, including the adrenal cortex, myocardial tissue, vascular flat muscle [6] , the kidneys and the brain. The effects of AII include modulating the liberation of aldosterone from the adrenal cortex adrenal [7] , the heart rate control [8] , vascular tonus [9] , glomerular filtration and the pituitary secretion of the vasopressin [10, 11] . AII also acts in the outlying central nervous system of mice [12] . These functions of AII can be altered in vascular diseases such as hypertension and arteriosclerosis, promoting the growth and hypertrophy of the flat and heart muscles [13] . An understanding of the AII-receptor interaction with the AII peptide is crucial for the control of the renin-angiotensin system; however, the greatest difficulty in achieving this goal is establishing the bioactive conformation of AII. Over many decades, the conformation of AII has been studied using different approaches, such as CD studies [14] , Raman spectroscopy [15] and NMR [16] [17] [18] . Structure-activity relationship studies focusing on AII have demonstrated the importance of the amino acid residues Tyr 4 , His 6 and Phe 8 for biological
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Abbreviations: AAA, Amino acid analysis; ACN, Acetonitrile; AII, angiotensin II; BOP, (Benzotriazol-1-yl-oxy)tris(dimethylamino)phosphonium hexafluorophosphate; BSA, bovine serum albumin; CD, Circular Dichroism; CE, Capillary Electrophoresis; CHO, Chinese hamster ovary; DCM, Dichloromethane; DIC, N,N′-Diisopropylcarbodiimide; DIPEA, N,N-Diisopropylethylamine; DMEM, Dulbecco's modified Eagle's medium; DMF, Dimethylformamide; DMS, Dimethyl sulfide; DMSO, Dimethyl sulfoxide; FAR-UV, FarUltraviolet; FFT, Fast Fourier Transform; Fmoc, Fluorenylmethyloxycarbonyl; HF, Hydrogen fluoride; HOBt, N-Hydroxybenzotriazole; IP, intraperitoneal; LC/ESI-MS, Liquid Chromatography/Electrospray Ionization Mass Spectrometry; MeOH, Methanol; NMP, N-methylpyrrolidone; OFm, Fluorenylmethyloxycarbonyl ester; RP-HPLC, Reverse-phase High-Performance Liquid Chromatography; Sar, Sarcosine; SDS, Sodium dodecyl sulfate; t-Boc, tert-Butoxycarbonyl; TBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate; TEAP, Triethylammonium phosphate; TFA, Trifluoroacetic acid; TFE, 2,2,2-trifluoroethanol.activity [19, 20] . The antagonistic activity of AII, characterized by slow receptor desensitization rates, can be obtained with an amino acid replacement. This antagonistic behavior is highly dependent on the nature of the amino acid in position 8 [21] and by aliphatic amino acids this peptide (Ile, Ala and Thr). AII competitive antagonists are also obtained by modifying the hydroxyl group of the Tyr 4 residue [22] .
In an attempt to characterize the bioactive conformation of this hormone, several cyclic analogues have been created by the incorporation of disulfide or lactam bridges and tested for their activity [23] [24] [25] . Among them, the following bridged monocyclic disulfides demonstrated high affinity for the AT1 receptor: c[Cys 3, 5 ]-AII, c[Cys [23, [26] [27] [28] [29] [30] [31] . In addition, cyclic analogues were created by inserting a lactam bridge in the same region of the molecule, which generated relevant antagonistic activity [27] .
In this work, we performed a systematic AII structure-activity relationship study using conformationally restricted analogues created via the incorporation of a lactam bridge. Peptides were designed by scanning the entire AII sequence with i-(i + 2) and i-(i+ 3) lactam bridges, consisting of an Asp-(Xaa) n -Lys scaffold. All the amino acids residues important for the biological activity of AII (i.e., His, Phe side chains, the hydroxyl group of Tyr, and the C-terminal carboxylic group) were left unchanged. The effect of lactamization was also evaluated by testing the corresponding linear analogues. The agonistic and antagonistic effects of the peptides were compared to AII using Chinese hamster ovary (CHO) cells transfected with the AT1-receptor and then grown in suspension on a Cytosensor microphysiometer. Furthermore, the contractile responses of isolated guinea-pig ileum and rat-uterus preparations as well as the arterial pressure alterations induced by the peptides were also evaluated. The conformational behaviors of the compounds were analyzed using circular dichroism (CD).
Experimental procedures

Peptide synthesis, purification and characterization
AII and its analogues were synthesized using a common protocol for manual solid-phase methodology and the tert-butoxycarbonyl (t-Boc) strategy [32, 33] . Chloromethylated resin [34] with a degree of substitution varying from 0.5 to 0.8 mmol/g was employed. The N α -terminal protecting group was removed with 50% trifluoroacetic acid (TFA) in dichloromethane (DCM) in the presence of 2% anisole for 20 min. Couplings were carried-out using a 2.5-fold excess of 1,3-diisopropylcarbodiimide/N-hydroxybenzotriazole (DIC/HOBt) in DCM-dimethylformamide (DMF) (1:1, v/v) and were monitored using the Kaiser ninhydrin test [35] . Recouplings for 1 h were performed when needed using a 2.5-fold excess of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) in the presence of N,N-diisopropylethylamine (DIPEA) in DCM/N-methylpyrrolidone (NMP) (1:1, v/v) [36] . Acetylations were performed using 50% acetic anhydride in DMF for 15 min, when required. Orthogonal protection of the aspartic acid side chain residues with OFm (Fluorenylmethyloxycarbonyl ester) and the lysine residues with Fmoc (9-fluorenylmethyloxycarbonyl) were employed. Side-chain to side-chain cyclization (lactamization) was performed with the peptide still attached to the resin [37] . After washes with DCM and DMF, the OFm and Fmoc groups were removed by treating the peptide with 20% piperidine in DMF [38, 39] .
The lactamization reaction was performed using a 3.0-fold excess of (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) to the peptide concentration in the presence of excess DIPEA in 20% dimethyl sulfoxide (DMSO) dissolved in NMP [37] and the reaction progress was monitored using the Kaiser ninhydrin test. Dry-protected peptidyl-resin was exposed to anhydrous HF in the presence of 5% anisole and 5% dimethyl sulfide (DMS) for 75 min at 0°C. Excess HF and scavengers were eliminated under high vacuum. The crude peptides were precipitated with anhydrous diethyl ether, separated from ether-soluble reaction components by filtration, extracted from the resin with 5% acetic acid in water and lyophilized. Crude lyophilized peptides were then purified by preparative reverse-phase high-performance liquid chromatography (RP-HPLC) in two steps: triethylammonium phosphate (TEAP) at pH 2.25 and 0.1% TFA on a Waters Associates system (Model Prep 4000). Briefly, the peptides were loaded onto a Vydac C 18 (25 mm × 250 mm, 15 μm particle size, 300 Å pore size) column at a flow rate of 10.0 mL/min and eluted using linear gradients (slope 0.33% B/min) of TEAP (pH = 2.25)/Acetonitrile (ACN) with detection at 220 nm. Selected fractions were collected and converted to the TFA salt by loading on a preparative column as described above and eluting with a linear gradient (slope 0.33% B/min) of solvents A (0.1% TFA in water) and solvent B (75% ACN in solvent A), at a flow rate of 10.0 mL/min. Selected fractions containing the purified peptide were pooled and lyophilized.
Purified peptides were characterized by liquid-chromatography electrospray-ionization mass spectrometry (LC/ESI-MS), capillary electrophoresis (CE) (Tables S1 and S2 in the Supplementary material), and amino acid analysis (AAA; data not shown).
LC/ESI-MS data were obtained on a Micromass instrument, model ZMD, coupled to a Waters Alliance system (model 2690) and photodiode array detector (model 996), using a Phenomenex Gemini C 18 column (2.0 mm × 150 mm, 3.0 μm particle size, 110 Å pore size). Capillary electrophoresis profiles were obtained using a Waters System, model CIA (Capillary Ion Analyzer), by hydrostatic injection in 25 s, utilizing phosphate buffer at pH 2.50, λ = 214 nm, a silica capillary (75 μm × 60 cm), voltage of 20 kV at a temperature of 30°C.
Amino acid analysis of the peptides previously hydrolyzed in 6 M HCl at 110°C for 72 h were performed by ion-exchange chromatography in a Biochrom 20 Plus amino acid analyzer, using the threebuffer system under standard conditions recommended by the manufacturer. The molar ratios of the amino acids were established by considering the concentration unitary of the closest amino acid of the average for all the residues.
Circular dichroism studies
Far-UV (190-250 nm) CD spectra were recorded at 20°C using a 1 mm path length quartz cell in a Jasco J180 spectropolarimeter. All spectra were recorded after an accumulation of four runs. The scan rate was 50 nm/min for all measurements with bandwidths of 0.5 nm. All peptides were measured in the following four solutions: water (pH=7.4), 20 mM sodium dodecyl sulfate (SDS), 50% 2,2,2-trifluoroethanol (TFE) in water, and 60% methanol (MeOH) in water. The CD spectra for the SDS, TFE and MeOH solutions were subtracted, and a Fourier transform filter (FFT) was applied to minimize background effects.
Cell culture and cell transfection
Chinese hamster ovary (CHO) cells were maintained in Dulbecco's modified Eagle's medium from GIBCO-BRL. DMEM was supplemented with 10% fetal calf serum and 100 UI/mL of gentamycin and maintained at 37°C in a humidified 5% CO 2 atmosphere. An expression plasmid containing the wild-type rat AT1 receptor was permanently transfected into CHO cells using the Lipofectin reagent (Life Technologies), as described by the manufacturer. Cells containing the inserted plasmid were selected for by the addition of G418 (500 mg/mL) in DMEM.
Extracellular acidification rate measurements
The use of a Cytosensor microphysiometer is a powerful technique to evaluate the responsiveness of different cell lines to a variety of bioactive ligands by measuring small changes in the concentration of H + ions in the sensor chamber [40] . This method has been used extensively to measure the effects of signal transduction after the application of cell surface receptor ligands, both agonists and analogues, for many families of G protein-coupled receptors [41] [42] [43] . Cells expressing the AT1 receptor were plated in DMEM onto membrane polycarbonate capsule cups at a density of 5 × 10 5 cells/ cup, approximately 18-24 h prior to the experiment. The capsule cup insert assembly was then placed into the pH-sensitive sensor chamber of the Cytosensor system (Molecular Devices Corporation) [41] . DMEM not supplemented with fetal calf serum was pumped through the chambers, bathing the cells at a rate of 100 μL/min. This running medium was devoid of sodium bicarbonate and had a 1 mM buffering capacity supplied by phosphate. Physiological osmolarity was obtained by the addition of NaCl. The assembled cup was then transferred to sensor chambers containing 1 mL of low buffered (1 mM sodium phosphate) DMEM containing 0.1% bovine serum albumin (BSA). This DMEM was without bicarbonate but contained 2 mM glutamine and an additional 44.4 mM NaCl as replacement for the bicarbonate and to adjust the osmolarity. The sensor chambers were placed on the Cytosensor and allowed to equilibrate for 30-40 min before the beginning of the experiment. Medium was pumped through the chambers at a rate of 100 μL/min, and the pump cycle was 90 s on followed by 20 s off at 37°C. To assess shifts in the extracellular acidification rate, cells were stimulated over a period of 30 s, with chemical compounds at concentrations of 10 −6 and 10 −7 mol/L. All measurements were performed in quadruplicate, and the data were analyzed by nonlinear regression analysis using PRISM 3.02 (Graph-Pad Software, San Diego, CA).
Bioassays
For isolated smooth muscle preparations, rats and guinea-pigs were killed by a blow to the head and exsanguinated [44] . Their organs were removed and mounted in an organ bath. All pharmacological experiments followed the current guidelines for the care and use of laboratory animals as well as the ethical guidelines for investigations, and these experiments were pre-approved by the Animal Care Committee of the Federal University of São Paulo. All bioassay experiments were carried out in triplicate and generated equivalent results. The biological potencies were calculated in relation to the AII sample, which was taken to be 100%.
Guinea-pig ileum
The lower portion of the ileum was excised from guinea pigs (250-350 g) and washed in warm Tyrode's solution with the following composition: 136.8 mM NaCl; 2.7 mM KCl; 1.36 mM CaCl 2 ; 0.49 mM MgCl 2 ; 0.36 mM NaH 2 PO 4 ; 11.9 mM NaHCO 3 ; and 5.5 mM glucose. Segments that were 4.5 cm in length were cut and suspended in 5-mL organ baths containing aerated Tyrode's solution bubbled with a gas mixture of 95% O 2 /5% CO 2 ; the temperature was maintained at 37°C. Preparations were mounted under a 1 g load and were connected to a lever front entry to record the isotonic contractile response, using with 6× magnification, in a kymograph (Palmer).
Peptides were dissolved in water (1.0 mg/mL), diluted in a 0.9% NaCl solution and added to the perfusion chambers, staying in contact with the organ for 90 s. After treatment, the preparation was washed and allowed to settle for 3.5 min (with an interval between doses of 5.0 min).
Rat-uterus preparations
Uterine horns from female Wister rats (200-250 g) that had received 100 mg diethylstilbestrol per 100 g body weight 48 h before the experiments were removed and mounted in 5-mL organ baths containing De Jalon's solution of the following composition: 137 mM NaCl; 5.36 mM KCl; 0.41 mM CaCl 2 ; 0.19 mM MgCl 2 ; 0.36 mM Na 2 HPO 4 ; 11.9 mM NaHCO 3 ; and 5.5 mM glucose. The solution was bubbled with a gas mixture of 95% O 2 /5% CO 2 , and the temperature was maintained at 30°C to inhibit the spontaneous contractions observed at higher temperatures. Preparations were mounted under a 1.5 g load and were connected to a lever front entry to record the isotonic contractile response, with 6× magnification, in a kymograph (Palmer).
Blood pressure measurements
Experiments were performed using male Wistar rats (290-300 g, n = 3 for each group). One day before the experiment, the rats were anesthetized (450 mg/kg chloral hydrate, ip -intraperitoneal), and a polyethylene catheter (PE-10 connected to PE-50) was inserted into the abdominal aorta, through the femoral artery, for blood pressure measurements. For intravenous injections, a polyethylene cannula was implanted into the femoral vein. The polyethylene cannula was closed by metallic pins and filled with isotonic saline and was driven subcutaneously to the interscapular region of the backs of the animals. After injections with an isotonic peptide solution, changes in arterial pressure were recorded using a transducer (Hewlett-Packard model FTA-10) through an amplifier (Hewlett-Packard model E805) and a potentiometric recorder (ECB model RB102).
Statistical analyses
The Kruskal-Wallis test and Dunnett's multiple comparison test (GraphPad InStat version 5.00 for Windows, GraphPad Software, San Diego, California, USA, www.graphpad.com) were used to assess the statistical significance of the differences between the control and the analogue-treated groups.
Results
Synthesis and characterization
Angiotensin II analogues were manually synthesized on a chloromethylated resin using the solid phase method and a t-Boc strategy. Main chain assembly was mediated by DIC, TBTU and BOP. Orthogonal protection of the side chains of the bridge-head components were employed to allow for cyclization with the peptide still attached to the resin. The best cyclization performance was obtained when lactamization was mediated by BOP in the presence of excess DIEA. Peptides were cleaved and deprotected in anhydrous HF and purified with RP-HPLC. All peptides were analyzed by CE, LC/ESI-MS and AAA. Peptide characterization by AAA and mass spectroscopy were in agreement with the expected theoretical values. Analysis by RP-HPLC and CE showed that all compounds were greater than 96% pure (Table S1 and Table S2 -Supplementary material).
Circular dichroism
Circular dichroism spectra for some peptides in water, in 20 mM SDS, in 50% TFE or in 60% MeOH are shown in Fig. 1. 
Biological assays
Bioassays using the Cytosensor microphysiometer measured the speed of acidification of the medium surrounding CHO cells transfected with AT1 angiotensin II receptor. These assays showed highly significant agonistic activities for the analogues, in comparison Fig. 2 and Table S1 ). The effect of lactamization was also evaluated and was shown to be important, as the linear analogues (compounds 2 (55%) and 4 (29%), Fig. 2 ) are significantly less potent than the corresponding lactamized peptides (compounds 1 (87%) and 3 (53%), Fig. 2 )]-AII (1) demonstrated the best bioactivity, we used this compound as a lead compound in the design of new AII analogues (compounds 5 to 10, Table 1 ). After further synthesis, the effects of chirality (compounds 5 to 7) and the length (compounds 8 to 10) of the bridgehead components on peptide activity was evaluated. It is clear that the chirality and bridge length are not critical for recognition by the AT1 receptor. The new analogues demonstrate a 20% increase in biological activity.
To discover new antagonists, we designed an AII antagonist series based on cyclo (3) (4) (5) concentrations; the results are presented in Fig. 3 .
Discussion
Many efforts have been made to establish the conformation of the AII molecule when it is attached to its receptor. Many techniques have been employed in this pursuit, including molecular modeling [45] , pseudopeptide design [46] and the synthesis and biological testing of conformationally constrained analogues, especially using side chain peptide cyclization, such as lactam or disulfide bridges [29] .
In this work, we continue to describe a systematic study of the structure-activity relationship of AII analogues that contain lactam bridges in their structures. The effects of structural restriction on the recognition of peptides by the AII-receptor were studied in vivo and in vitro. Moreover, a conformational study was performed using circular dichroism in an attempt to correlate the biological activity with the secondary structures of the AII analogues.
In the CD spectra for AII in water (Fig. 1A) , we observed a negative minimum below 200 nm. This minimum is primarily associated with unfolded and/or random conformations, suggesting that this peptide mainly adopts a random structure in water, as is expected for small peptides in solution. The addition of SDS, TFE or MeOH induced some folded secondary structure in the AII peptide. This acquisition of regular structure is suggested by the appearance of negative minima near 225 nm and by the appearance of slightly positive maxima near 200 nm, which are characteristic of beta elements [47] . The structure induced with the addition of TFE is in agreement with the recently proposed model by Spyroulias and collaborators [48] for AII in the presence of 2,2,2 trifluoroethanol in water. In this model, AII presents an S-shape backbone conformation with the existence of beta-turn-like structures. Although the U-shape has been proposed to be essential for the biological activity of this peptide, the transformation of the S-shape conformation to a functional U-shape conformation is an important point to consider. Because this cooperative transformation decreases the possibility of π-π* stacking geometry between tyrosine and histidine residues, these two residues would be able to emerge from the stacking structure, stimulating a response from the receptor [48] .
The spectra of analogues 1 and 2, which are shown in Fig. 1B and C, respectively, present a similar behavior. The negative minimum near 200 nm for the peptide in water also suggests that these analogues adopt a random conformation in water, similar to the native angiotensin II. When SDS, MeOH or TFE were added, the CD spectra of both analogues 1 and 2 showed a negative minimum near 225 nm and a positive maximum below 200 nm, suggesting the presence of beta structures.
This conformational change is more evident in analogue 1 than in analogue 2 and could be correlated with the biological results obtained for analogue 1, which demonstrated a potency similar to AII (Fig. 2) . These analogues are the only ones that allow placement of the Arg2, Tyr4, Ile5 and His6 side chains to the same side, as proposed by Tzakos [49] . Analyzing the results, we can suggest that the Nterminal portion of the AII molecule is more susceptible to alterations than the remainder of the molecule and that analogue 1 adopts a structure similar to AII. The side chain-to-side chain bridging cyclization, observed in analogue 2, produces a significant effect on the biological activity, which decreased more than 30% in all bioassays evaluated, with exception of the measurements of rat blood pressure, which are similar to the controls. Our results are in agreement with other studies. Schreier et al. synthesized and tested AII analogues containing the paramagnetic amino acid TOAC in several positions of the AII molecule [50] . The authors obtained the equipotent analogue (TOAC 1 -AII), which had replaced the amino acid residue Asp 1 with TOAC. In another work, Motta et al. [51] have shown that an N- terminal modification using Fmoc-or OFm-type groups coupled to the Asp 1 residue induced tachyphylaxis via an alternate mode of molecular interaction between the N-terminal portion of AII and its AT1 receptor.
In an attempt to evaluate the chirality and size of the lactam ring, we exchanged the Asp and Lys residues of the analogue cyclo(0-1a) [Asp 0 , endo-(Lys 1a )]-AII (1) for D-Asp or L-Glu and for D-Lys or L-Orn residues, respectively. In general, we observed a 20% increase in the biological activity (in vitro), as compared with analogue 1 (Fig. 2) , and we obtained different results when studying the isolated smooth muscle preparations and for the rat blood pressure measurements (Table 1) . Based on these results, we suggest that the size, chirality and bridgehead elements of the lactam bridge are not so important for recognition and binding to the AII AT1-receptor because these exchanges should not affect the U-shaped structure of the Tyr4-Ile5-His6-Pro7 sequence [49] .
In water, the CD spectrum of analogue 8 presents a negative minimum near 200 nm that is shifted to 225 nm when SDS, TFE or MeOH is added. This minimum, together with the presence of a positive maximum near 200 nm, indicates the presence of regular structures, mainly beta elements. Moreover, all the peptides in the same group as analogue 8 (peptides 5 to 10) presented equivalent conformational changes (data not shown). It is interesting to note that analogues 1 and 2 as well as 5 through 10 demonstrated biological activity in all the bioassays tested and that their conformations can be affected by SDS, TFE or MeOH in a similar way to that of the native angiotensin II. These studies clearly indicate a similarity in the conformational behavior of the analogues with that observed for the native AII, which is shown by NMR to possess a bend that is stabilized by interactions between residues 3 and 4 (Val and Tyr) [52] . In contrast, CD studies of the inactive analogues (Table S2) show that the addition of SDS, TFE or MeOH did not induce important changes in the secondary structure of these compounds (e.g., [endo- (Asp 6a ) and endo-(Lys 7a )]-AII; Fig. 1E ), which show similarity to the spectra obtained in both water (with a minimum at 199 nm) and the other solvents. In fact, the solvent medium caused a very small shift in the negative minimum (from 199 nm to 203.5 nm or 205 nm), indicating mainly unordered conformations and no considerable changes to the secondary structure.
Our results show that an insertion of Lys and Asp residues in another region of the AII molecule exerted a negative effect in the biological assays (analogue 4), even producing inactive analogues (Table S2 ). This fact is probably due to the side chain charge for these residues (in the linear analogues) or changes in the distances between the amino acids residues that are important in facilitating the biological activity of AII (i.e., Asp , who have suggested a fairly compact folded structure for AII [49] . The antagonistic results obtained (see Fig. 3 ) show that analogues 11 to 15 do not inhibit the AII response at two different concentrations (10 −6 mol/L and 10 −7 mol/L). In contrast, analogue 16 demonstrated approximately 35% inhibition at both concentrations tested. When we compare the primary sequence of analogues 16 and 11, we hypothesize that the increased potency may be due to the absence of the isoleucine residue. This isoleucine might induce or stabilize a backbone turn conformation when the peptide interacts with the receptor [53] . Thus, in analogue 16, the lactam bridge probably mimicked the interaction between Arg2 and Ile5. These antagonist analogues do not show changes in their secondary conformations in the presence of SDS, TFE or MeOH. CD spectra of analogue 12 ( Fig. 1F ) in water or in the presence of SDS, TFE or MeOH present a negative minimum near 225 nm. The spectra of the peptide in water or in SDS show an unusual behavior, indicated by the presence of a negative peak near 200 nm, as opposed to a positive maximum. Nevertheless, the negative minima, which are characteristic of structures with high beta content, are present in the peptide spectra taken in water. The overall shapes of the spectra remain unaltered upon the addition of SDS, TFE or MeOH. All spectra for this group of analogues presented this unusual shape, similar to Wilkes's antagonists [53] , and this can be attributed to the presence of a Sar residue, which can disturb the beta structure. This kind of approach may offer the basis for the development of new drugs to be used in the treatment of hypertension. Supplementary materials related to this article can be found online at doi:10.1016/j.regpep.2011.05.015.
